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ABSTRACT
Endomyocardial biopsy (EMB) is central to the
diagnosis of giant-cell myocarditis (GCM) and
planning furthermanagement.There is, however,
no guideline-directed recommendation on
re-biopsy or left ventricular EMB in a suspected
case of acute, fulminant myocarditis following
an indeterminate first biopsy. This manuscript
illustrates, with a case, the changing role for EMB
in the current era in the diagnosis of GCM.
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INTRODUCTION
Giant-cell myocarditis (GCM) is a rare disease
that is characterized by diffuse inflammatory
infiltration of the myocardium with
lymphocytes and multi-nucleated giant cells in
the absence of granulomas [1]. It most
commonly presents as heart failure with
ventricular arrhythmias and cardiac
conduction abnormalities [1]. The clinical
course in GCM is typically fulminant, with
ensuing death or cardiac transplantation within
hours or days of presentation, despite initiation
of guideline-directed medical therapy [1].
Endomyocardial biopsy (EMB) is key in
establishing the correct diagnosis, and planning
further management. There is, however, no
guideline-directed recommendation on re-biopsy
or left ventricular (LV) EMB in a suspected case of
acute, fulminant myocarditis following an
indeterminate first biopsy. This manuscript
illustrates, with a case, the changing role for EMB
in the current era in the diagnosis of GCM.
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CASE REPORT
Informed consent was obtained from this
patient for being included in the paper.
HISTORY
A 50-year-old male presented to his primary
care physician in rural Minnesota (United
States) with progressive shortness of breath
and functional limitation of 2-month
duration, following antecedent viral upper
respiratory infection. The patient also reported
dizziness, lightheadedness, palpitations, and
chest tightness with physical activity.
Twenty-four-h ambulatory electrocardiographic
(Holter) monitoring demonstrated sustained
monomorphic slow ventricular tachycardia
(VT) at 106 beats per minute. He was admitted
to a local hospital. Cardiac troponin I (cTnI) was
elevated at 3.66 ng/mL (reference \0.034 ng/
mL). Brain natriuretic peptide level was
5,500 pg/mL (reference 4–40 pg/mL). A
transthoracic echocardiogram showed globally
depressed LV systolic function with marked
septal dyssynchrony; estimated ejection
fraction was 25–0%. Right ventricular systolic
function was moderately reduced with biatrial
enlargement. There was no significant valvular
abnormality or pericardial effusion. The patient
was treated with intravenous heparin and
amiodarone, and transferred to our
tertiary-care center for further evaluation and
management.
The past medical history was significant for
essential hypertension and hyperlipidemia. The
patient was a lifelong non-smoker and reported
consumption of 4–6 units of alcohol per day.
There was no history of illicit drug use. The
family history was significant for chronic
granulomatous disease in a brother who died
at age 48 of Staphylococcal sepsis. His maternal
grandparents had died in their early 1940s of
unknown causes. He had never traveled outside
the United States. Prescription medications
included atenolol, amlodipine, lisinopril–
hydrochlorothiazide, and simvastatin.
PHYSICAL EXAMINATION
On physical examination, the patient’s
temperature was 37.3 C (99.1 K), his heart rate
was irregular at 102 beats per minute, his blood
pressure was 102/80 mmHg, his respiratory rate
was 13 breaths per minute, and his oxygen
saturation (via pulse oximetry) was 97% on 3 L/
min on inhalational oxygen via nasal cannula.
The jugular venous pressure was elevated at
15 cmH20. The point of maximal impulse was
palpated in the 6th intercostal space, 3 cm
lateral to the midclavicular line. Heart sounds
were distant. There was an S3 gallop with
minimal bibasilar crackles on cardiopulmonary
auscultation. Hands and feet were warm with
intact peripheral pulses. There was trace pedal
edema. Review of systems was otherwise
unremarkable.
DIAGNOSTIC STUDIES
Laboratory tests, including a complete blood
count and basic metabolic panel, as well as an
international normalized ratio and activated
partial thromboplastin time were within
normal limits. Chest roentgenogram
demonstrated a mildly enlarged cardiac
silhouette. A 12-lead electrocardiogram (EKG)
showed normal sinus rhythm with low-voltage
QRS complexes (134 ms), Q waves in leads III &
aVF, poor R-wave progression and evidence of
left atrial enlargement. cTnI was elevated at
3.351[2.915 ng/mL (reference \0.034 ng/mL).
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Coronary angiography revealed minimal non-
obstructive epicardial coronary artery disease;
the LV end-diastolic pressure was 36 mmHg.
Right heart catheterization showed elevated
right- and left-sided filling pressures and
evidence of cardiogenic shock [right atrial
pressure of 23 mmHg, right ventricular (RV)
pressure of 33/20 mmHg, pulmonary artery
pressure of 42/34 mmHg, mean pulmonary
artery pressure of 38 mmHg, pulmonary
capillary wedge pressure of 23 mmHg, and a
Fick cardiac index of 1.4 L/min/m2]. A cardiac
magnetic resonance imaging (cMRI) scan with
gadolinium demonstrated a mildly enlarged
and severely hypokinetic left ventricle with
prominent septal dyssynchrony. There was
focal delayed hyper-enhancement on T1-
weighted imaging in the mid-inferior wall and
mid-inferior septum (Fig. 1).
An EMB from an MRI-guided site in the RV
septum showed extensive fibrotic replacement of
the myocardium with associated scattered fatty
tissue and limited chronic inflammation. Iron
and crystal violet staining were negative for iron
and amyloid deposition. There was no serologic
evidence of a co-morbid autoimmune disorder.
He had sustained slow monomorphic VT,
refractory to pace-termination in the cardiac
catheterization laboratory. Electrophysiology
study demonstrated multiple inducible VTs at
variable cycle lengths with extensive low-voltage
area in right ventricle and inhomogeneous scar
in the inferoseptal and anterolateral walls of left
ventricle.
The patient was emergently listed for
cardiac transplantation and a
pre-transplantation immunosuppressive
regimen of methylprednisolone and
mycophenolate mofetil was administered.
Orthotopic heart transplantation was
performed. He succumbed to post-cardiotomy
shock requiring vasopressor and inotropic
support post-transplantation. Pathology of the
explanted heart revealed florid GCM with
extensive replacement fibrosis involving the
interventricular septum (IVS) (Fig. 2) and the
LV free wall. There was acute hemorrhagic
infarction of the IVS. Histopathology
demonstrated multi-nucleated giant cells with
hypereosinophilic and necrotic cardiac myocytes
(Fig. 3).
DISCUSSION
The diagnosis of GCM is established by a
conglomerate of laboratory and radiographic
Fig. 1 Cardiac magnetic resonance imaging: T1-weighted images demonstrating delayed hyper-enhancement (arrows) in
mid-inferior/septal walls
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investigations. Biomarkers of cardiac injury,
troponin I and T are typically constitutively
elevated, with a lack of rise-and-fall pattern, and
reliably predict severity of myocarditis and
short-term prognosis [1]. There are no
pathognomonic EKG changes that occur in
GCM. Electrocardiographic abnormalities
include sinus tachycardia and non-specific
ST changes, and T-wave abnormalities.
Occasionally, patients can present with
ST-elevation on the surface EKG, with
pathologic Q waves. Presence of pathologic Q
waves, and QRS duration [120 ms have been
shown to predict an increased risk of death or
cardiac transplantation [2]. The most common
echocardiographic finding in acute myocarditis
is a dilated, spherical left ventricle with reduced
systolic function. Concomitant RV dysfunction
portends a poor prognosis. cMRI can be a useful
tool, and is being utilized with increased
frequency, but has not been extensively
studied in GCM [3].
Endomyocardial biopsy is central to the
diagnosis of GCM, as it is a pathologic
diagnosis. The earliest use of EMB was reported
by Sakakibara and Konno [4], using the Konno
bioptome via the basilic vein and axillary artery.
Biopsy specimens were obtained from five
patients without complications. In all cases, a
substantially more accurate histological
diagnosis was obtained via EMB than had been
established clinically [4]. More recent
investigations suggest an important prognostic
roleofEMB in thediagnosis of cardiomyopathies.
Felker et al. [5] followed 1,230 patients with
unexplained cardiomyopathy who underwent
EMB and right heart catheterization.
Approximately 50% of patients demonstrated a
specific cardiomyopathy, and 15% were given a
specific histological diagnosis via EMB. The study
demonstrated that survival in patients with
myocarditis was not significantly different than
patients with idiopathic cardiomyopathy. While
the prognostic value of EMB in cardiomyopathy
was aptly demonstrated in this study, only a
small percentage of the original study population
was given a specific histological diagnosis from
EMB [5]. Another more recent study specifically
examined long-term survival rates among 147
patients diagnosed with either fulminant or
acute myocarditis [6]. Biopsied specimens were
taken from the RV septum, and analyzed using
the Dallas criteria (inflammatory infiltrate and
associated myocyte damage not characteristic of
Fig. 2 Extensive replacement ﬁbrosis of the interventric-
ular septum (IVS) (arrowheads) with acute hemorrhagic
infarction of the IVS (arrow)
Fig. 3 Interface (arrows) between active giant-cell
myocarditis and viable normal myocardium (NM) with
hypereosinophilic and necrotic cardiac myocytes (asterisk).
Multi-nucleated giant cells (arrowheads) are seen invading
into NM
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ischemic event). Patients with fulminant
myocarditis, while critically ill at presentation,
maintained better long-term survival outcomes
than patients presenting with acute myocarditis
[6]. While considerable progress has been made
in obtaining an EMB specimen, histological
diagnosis of myocarditis still poses considerable
limitations. The diagnosis of myocarditis, as
described by the 1986 Dallas criteria, arguably
has limitations in sampling error, discrepancies
among investigator interpretation, differences in
viral and immune marker expression in the
myocardium, and varying degrees of response
to therapy among Dallas criteria myocarditis [7].
The 2007 American Heart Association
(AHA)/American College of Cardiology
Foundation (ACCF)/European Society of
Cardiology (ESC) scientific statement on EMB
gives it a class I recommendation in the setting
of an unexplained new-onset heart failure of
2-week duration with a normal-size or dilated
left ventricle and hemodynamic compromise,
or unexplained new-onset heart failure of
2-week to 3-month duration with a dilated left
ventricle and new ventricular arrhythmia, or
second- or third-degree atrioventricular block,
or in patients who do not respond to usual
care within 1–2 weeks [8]. The 2013 ESC
Working Group on Myocardial and Pericardial
Diseases position statement also supports the
aforementioned recommendation [9]. However,
the sensitivity of EMB for GCM decreases with
duration of symptoms [10]. In a study by
Kandolin et al. [11] of 72 young adult patients
aged 18–55 years with initially unexplained
atrioventricular block in whom GCM was
found in 6% (n = 4) of cases [19% (n = 14)
were diagnosed with cardiac sarcoidosis], EMB
had a 25% diagnostic rate, comparable to that
reported in a prospective GCM registry (28%)
where the criteria for biopsy were an acute
cardiomyopathy complicated by heart block,
ventricular arrhythmias, or lack of response to
usual care [11, 12]. The sensitivity of RV EMB is
80–85% in GCM, and its yield is significantly
improved if prior site localization is done with
cMRI [10, 13]. In addition, sensitivity of EMB
has been shown to increase from 68% to 93%
upon re-biopsy in GCM patients [11]. None of
the guidelines currently recommend re-biopsy
in a suspected case of acute, fulminant
myocarditis where the first biopsy is
inconclusive or discordant with the clinical
scenario, as demonstrated by our case, where
the EMB was non-diagnostic but had features
suggestive of arrhythmogenic RV
cardiomyopathy/dysplasia (ARVC/D).
Clinically, however, there was a high index of
suspicion for GCM given the history of an
immune disorder in a first-degree relative, VT of
right bundle branch morphology as the
presenting manifestation, typical cMRI
features, and fulminant clinical course despite
optimal medical therapy. The value of EMB
depends on the availability of expert
cardiovascular pathology. Routine evaluation
of EMB specimens includes formaldehyde-fixed,
hematoxylin and eosin-stained sections.
Depending on the clinical questions, elect
samples may be sent after glutaraldehyde
fixation for electron microscopy or freshly
frozen (or preserved with ribonuclease
inhibitors) for viral genome analysis.
Also, LV EMB, a procedure that is rarely
performed in medical centers across the United
States, could have provided crucial diagnostic
information in our case due to predominant LV
involvement. This is supported by the recently
published data on safely performing LV EMB in
the largest case series to date, by Chimenti and
Frustaci [14]. A total of 4,221 patients
underwent EMB; 1,153 underwent LV EMB,
672 RV EMB, and 2,369 both LV and RV EMB.
The overall risk of major complications was
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remarkably low over the 28-year period of the
study, lower with LV than RV EMB (0.33% vs.
0.45%, respectively), probably due to thinner
RV free wall [13]. The diagnostic yield was
higher with LV EMB, of disorders primarily
affecting the left ventricle, compared to RV EMB
(97.8% vs. 53%, respectively) [15]. Surprisingly
enough, the diagnostic yield of LV EMB was
higher for ARVC/D, a disorder that primarily
affects the RV ‘‘triangle of dysplasia’’ [16].
Another study by Yilmaz et al. [17], comparing
right and LV EMB in 755 patients with
suspected myocarditis and/or non-ischemic
cardiomyopathy, observed similar
complication rates in left and RV EMB (0.64%
vs. 0.82%, respectively). Biventricular EMB
yielded more frequent diagnostic results
(79.3%) compared to left or right ventricle-
selective EMBs (67.3%, P\0.001) [17]. In
clinical scenarios in which the left ventricle if
solely or primarily affected, LV biopsy may add
substantially to the sensitivity of EMB for the
diagnosis of myocarditis and probably GCM
[18, 19].
The diagnostic accuracy can be optimized
when the EMB is performed by experienced
cardiac interventionalists, sampling error
reduced by performing EMB early in the
course of the disease, and taking multiple
samples, at least 3, each 1–2 mm in size from
either the right or the left ventricle [15], and
performing immunohistochemistry and viral
genome amplification for assessment of
suspected myocarditis [18].
CONCLUSION
Acute GCM is a life-threatening condition that
requires prompt evaluation, initiation of
immunosuppressive therapy and consideration
for mechanical circulatory support or cardiac
transplantation. EMB is pivotal to establish the
correct diagnosis, and should be included in the
diagnostic algorithm for fulminant myocarditis.
The AHA/ACCF/ESC scientific statement on
EMB does not discuss re-biopsy of the RV, or
proceeding further to LV EMB to improve
diagnostic accuracy [8]. If the results of the
first RV EMB are inconclusive or discordant with
the clinical scenario, then re-biopsy or LV EMB
should be considered in the clinical scenario of
fulminant myocarditis.
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